Pulmotect

About:

Pulmotect develops an inhaled therapeutic designed to prevent and treat respiratory infections.

Website: http://pulmotect.com/

Twitter/X: pulmotect

Top Investors: National Institutes of Health, Cancer Prevention and Research Institute of Texas, National Heart, Lung and Blood Institute, Jefferson River Capital, Fannin Innovation Studio

Description:

Pulmotect is a biopharma company that develops products that boost the innate immune system to protect against a wide range of lung infections. Its technology stimulates the body’s natural defenses to provide safe, broad-spectrum, fast-acting protection against bacterial pneumonia (including MRSA), influenza, fungal pneumonia, and Class A bioterror agents (including anthrax, tularemia, and plague). The company was founded in 2007 and is headquartered in Houston, Texas.